Immune targeted therapy for diffuse large B cell lymphoma
Abstract. Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, is highly heterogeneous and invasive. Although the majority of DLBCL patients show a good response to rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone treatment, approximately o...
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Wolters Kluwer Health
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/75a8f873e7dc4771afaed696df2c52a6 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|